Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells are prompted to die. The work may help scientists to eventually develop new treatments for the many common diseases and conditions which occur when cell death goes wrong.
The research, published in leading journal Molecular Cell  today (Friday 14 August 2009) was carried out by a team of scientists, at the MRC Toxicology Unit at the University of Leicester and a subsequent patent application has been filed by MRC Technology, the commercial arm of the MRC.
Cells in the human body are continually dying and most of these cells kill themselves by a form of cell death, commonly referred to as apoptosis. In a healthy body, the number of cells stays constant. Millions of new cells are produced every second, and millions of others are lost or kill themselves. Failure of the normal apoptosis process plays a role in different diseases including cancer, certain neurodegenerative disorders such as Parkinson's and immune diseases, such as autoimmune lymphoproliferative syndrome (ALPS).
One of the study's authors, Dr Marion MacFarlane, MRC Toxicology Unit, explained: "This new research takes us a step closer to understanding how the DISC triggers cells to die. The challenge now is to try and use this fundamental knowledge to help work towards finding better treatments for conditions which occur when DISC-mediated cell death goes wrong."
Previous research has shown that a complex called the 'DISC', which is made up of different proteins and is formed following activation of molecules called 'Death Receptors', can trigger apoptosis by 'switching on' key players in the cell death process. However, previous research has found that the DISC can also activate cell survival, thus raising the question as to how paradoxically the 'DISC' can trigger these opposing cellular outcomes?
Now, scientists at the MRC Toxicology Unit have found that the DISC can trigger cell death or cell survival by switching the activity of key death-promoting molecules. Stopping the 'DISC' from functioning properly prevents the cell death programme from being carried out efficiently and instead results in cell survival. Thus, in diseases such as ALPS, where a crucial death-promoting protein is often not active the DISC fails to function properly.
For further information and to arrange an interview with colleagues on this project, please contact Nicola Osmond-Evans in the MRC Press Office on 0207 670 5138 or firstname.lastname@example.org
Notes to editors:
 "Reconstitution of the Death-Inducing Signalling Complex reveals a novel Substrate Switch that determines CD95-mediated Death or Survival" Molecular Cell
A copy of the Molecular Cell paper is available on request from Cathleen Genova at Cell Press on 001-616-397-2802 or email@example.com
The Medical Research Council is dedicated to improving human health through excellent science. It invests on behalf of the UK taxpayer. Its work ranges from molecular level science to public health research, carried out in universities, hospitals and a network of its own units and institutes. The MRC liaises with the Health Departments, the National Health Service and industry to take account of the public's needs. The results have led to some of the most significant discoveries in medical science and benefited the health and wealth of millions of people in the UK and around the world. www.mrc.ac.uk
About Medical Research Council Technology (MRCT) MRCT is the exclusive commercialisation agent for the UK Medical Research Council, working to translate cutting edge scientific discoveries into commercial products. MRCT bridges the gap between innovative basic science and making medicine. By providing drug-like candidate molecules to innovative new drug targets, we give pharmaceutical and biotechnology companies new starting points for drug discovery and development, based on MRC advances in science. www.mrctechnology.org
MRC press contact: 020 7637 6011 firstname.lastname@example.org
University of Leicester Press Office Contact:
Division of Marketing and Communications
University of Leicester
tel: 0116 252 3335
ABOUT THE UNIVERSITY OF LEICESTER
A member of the 1994 Group of universities that share a commitment to research excellence, high quality teaching and an outstanding student experience.
Named University of the Year by Times Higher (2008) Shortlisted (2006, 2005) and by the Sunday Times (2007)
Ranked top with Cambridge for student satisfaction amongst full time students taught at mainstream universities in England
Ranked as a Top 20 university by the Sunday Times, Guardian,Times and UK Complete University Guide, published in The Independent
Ranked in world's top 200 universities by Shanghai Jiao Tong International Index, 2005-08 and the Times Higher Education-QS World University Rankings
Ranked top 10 in England for research impact by The Guardian
Students' Union of the Year award 2005, short listed 2006 and 2007
Founded in 1921, the University of Leicester has more than 20,000 students from 136 countries. Teaching in 18 subject areas has been graded Excellent by the Quality Assurance Agency- including 14 successive scores - a consistent run of success matched by just one other UK University. Leicester is world renowned for the invention of DNA Fingerprinting by Professor Sir Alec Jeffreys and houses Europe's biggest academic Space Research Centre. The latest Research Assessment Exercise adjudged Leicester to have world leading research in every subject panel and identified Museum Studies (at 65%) as having the highest proportion of world leading researchers compared with any other subject area at any university in the UK. Leicester also emerged as having one of the highest proportions of staff who are research active in the UK, with approximately 93% of staff submitted for the exercise. The University's research grant income places it among the top 20 UK research universities. The University employs over 3,000 people, has an annual turnover of over £200m, covers an estate of 94 hectares and is engaged in a £300m investment programme- among the biggest of any UK university.